BioTech/Drugs - Vancouver, BC, CA
We are a pharmaceutical company discovering and developing novel drug candidates to treat inflammation and blood cancers. Our primary focus is anti-inflammatory product candidates targeting SH2-containing inositol-5'-phosphatase 1, or SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. Aquinox has a broad intellectual property portfolio and pipeline of preclinical drug candidates that activate SHIP1.
DNS Made Easy
Mobile Friendly